Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wockhardt Latest Indian Drug Maker To Split Off R&D

This article was originally published in PharmAsia News

Executive Summary

India's Wockhardt plans to form its research and development business into a new company to be listed on the stock exchange in 2009. Wockhardt would become the latest of several major drug makers in India to split their R&D work from their other drug-development activities. The separation is seen by companies as a way to raise more funds to support research while reducing the risks to core business. But one analyst said Wockhardt is not likely to see the benefits of delisting as much as its rivals because its drug pipeline is small. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts